The respiratory system is among the important systems of a human body. It plays a vital part in breathing. The breathing is typically consistent, which is automatically controlled by the respiratory center at the brain’s base. Apart from this, the respiratory system also assists in stabilizing the blood alkaline balance, regulating the temperature, and eliminating the toxic waste. Respiratory diseases prevent this normal functioning of the respiratory system and are typically caused due to unhealthy lifestyles, smoking, and the inhalation of hazardous agents. As per the report, the worldwide respiratory disease testing market was priced for around USD 2.5 Billion in 2015 and is projected to achieve around USD 3.1 Billion by 2021, emerging at a 3.6% CAGR between 2016 and 2021.

Sample Report is available at

Respiratory tests, including lung volume, blood gas test, spirometry, imaging, peak flow test, and few other tests are utilized to analyze the respiratory disease. Tools utilized to identify pulmonary abnormalities have huge potential owing to rising occurrence of different respiratory diseases Furthermore, the improvement in technology and the rising elderly population is expected to fuel the growth of the worldwide respiratory disease testing market. Nevertheless, the portable spirometers and decreased acceptance rate of digital radiography may hamper the market growth in the near future.

The worldwide market is segmented on the basis of the type of test and end-users. The type of the test segment of the market is classified into peak flow test, an imaging test, spirometry, lung volume test, blood gas test, and other tests. The end-users segment of the market is diversified into hospitals, clinical laboratories, and physician offices. The hospitals occupy the biggest share in the market of respiratory disease testing in 2015.

The key players in the market are Carestream Health, Inc., ndd Medical Technologies, Inc., Nihon Kohden Corporation, SDI Diagnostics, Smiths Medical, CareFusion Corporation, Perkin Elmer, Inc., COSMED, MGC Diagnostic Corporation, Philips Healthcare, Futuremed America, Inc., GE Healthcare, and Philips Healthcare among others.

Browse detail report @

At present, GlaxoSmithKline and Nottingham Respiratory Research Unit have devised an app named “MyAsthma.” This app enables the asthma patients to manage and track their condition, which further opens an avenue for respiratory disease testing.